Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of Escherichia coli to fluoroquinolones in urology

被引:42
作者
Wagenlehner, F
Stöwer-Hoffmann, J
Schneider-Brachert, W
Naber, KG
Lehn, N [1 ]
机构
[1] Univ Regensburg, Inst Med Microbiol, D-93053 Regensburg, Germany
[2] St Elizabeth Hosp, Dept Urol, Straubing, Germany
[3] Tech Univ Munich, Inst Med Microbiol, D-8000 Munich, Germany
[4] Univ Kiel, Inst Immunol, Kiel, Germany
关键词
antimicrobial prophylaxis; Escherichia coli; quinolone resistance;
D O I
10.1016/S0924-8579(00)00182-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
During the years 1991-1996 an increase in fluoroquinolone-resistant Escherichia coli was observed at the Urological Department of the Municipal Hospital in Straubing, Germany. A prospective study was undertaken to investigate the influence of single-dose prophylaxis (SDP) using 500 mg ciprofloxacin orally on the level of resistance to ciprofloxacin of faecal E. coli. One hundred and five patients were recruited to the study: E. coli resistance to ciprofloxacin before prophylaxis was 3% (3/91) in contrast to 12% (5/42) after prophylaxis (P = 0.052). In 31 isolates no major change in the low MIC values before and after SDP was observed. PFGE showed clonal diversity in about half of the cases. Three isolates showed low-level resistance and three isolates high-level resistance to ciprofloxacin both before and after SDP. PFGE showed clonal identity in all cases. All patients had previously been treated with fluoroquinolones (FQ). In two isolates emergence of high-level resistance to ciprofloxacin after SDP occurred. PFGE showed clonal diversity in both cases. We conclude that after SDP with 500 mg ciprofloxacin there is a shift to Gram-positive bacteria in the faeces and an increase in the rate of FQ resistance. Since selection of highly resistant E. coli is possible, a careful risk-benefit evaluation of prophylaxis with FQ is indicated. (C) 2000 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 42 条
[11]   DNA gyrase, topoisomerase IV, and the 4-quinolones [J].
Drlica, K ;
Zhao, XL .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) :377-+
[12]   Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals [J].
Everett, MJ ;
Jin, YF ;
Ricci, V ;
Piddock, LJV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2380-2386
[13]   Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones [J].
Goldman, JD ;
White, DG ;
Levy, SB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1266-1269
[14]   CHARACTERIZATION OF FLUORO QUINOLONE-RESISTANT MUTANTS OF ESCHERICHIA-COLI SELECTED IN-VITRO [J].
HEISIG, P ;
TSCHORNY, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) :1284-1291
[15]   MUTATIONS IN THE GYRA GENE OF A HIGHLY FLUOROQUINOLONE-RESISTANT CLINICAL ISOLATE OF ESCHERICHIA-COLI [J].
HEISIG, P ;
SCHEDLETZKY, H ;
FALKENSTEINPAUL, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :696-701
[16]  
Hooper D C, 1995, Drugs, V49 Suppl 2, P10
[17]   MODE OF ACTION OF THE NEW QUINOLONES - NEW DATA [J].
HOOPER, DC ;
WOLFSON, JS .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (04) :223-231
[18]  
*INT ANT THER COOP, 1996, ANTIMICROB AGENTS CH, V40, P387
[19]   1ST CLINICAL ISOLATE OF HIGHLY FLUOROQUINOLONE-RESISTANT ESCHERICHIA-COLI IN SCANDINAVIA [J].
JONSSON, M ;
WALDER, M ;
FORSGREN, A .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1990, 9 (11) :851-853
[20]   EMERGENCE OF FLUOROQUINOLONE-RESISTANT ESCHERICHIA-COLI AT A CANCER CENTER [J].
KERN, WV ;
ANDRIOF, E ;
OETHINGER, M ;
KERN, P ;
HACKER, J ;
MARRE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :681-687